Skip to main content
SpringerLink
Log in

Erlotinib cost effective for NSCLC in the US

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. willingness-to-pay

Reference

  • Ting J, et al. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States. Value in Health 18: 774-82, No. 6, Sep 2015. Available from: URL: http://doi.org/10.1016/j.jval.2015.04.008

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erlotinib cost effective for NSCLC in the US. PharmacoEcon Outcomes News 738, 14 (2015). https://doi.org/10.1007/s40274-015-2496-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2496-9

Search

Navigation